Abstract 1958P
Background
HN-STS is a challenging disease due to its diverse clinical presentation. In an attempt to refine the prognostication of these pts, the AJCC in its 8th edition proposed a new dedicated T staging group based on cutoffs of 2 and 4 cm for classifying T1, T2 and T3, and surrounding tissue invasion as T4, as opposed to the dichotomic T1-T2 5cm cutoff adopted by the 7th AJCC.
Methods
This is a retrospective study of pts diagnosed with nonmetastatic HN-STS treated with curative intent in a single tertiary hospital, approved by the institutional ethical review committee. The aim was to compare the 8th AJCC T staging to the previous classification as a prognostic tool for HN-STS, added to other variables such as age, histological subtype, grade and regional lymph node metastasis (LNM). AJCC 7th and 8th have been compared regarding T staging with Cohen’s kappa coefficient (KC) using inter-rater agreement analysis. The Kaplan-Meier estimator was used to calculate median survival time and differences in time-to-event outcomes were assessed using the log-rank test. Cox proportional hazard model was used to assess the effect of features in overall survival (OS).
Results
From 1997 to 2000, 135 pts were identified in institutional archives. Sarcoma NOS (N=50) and Leiomyosarcoma (N=17) were the most common histologic subtypes, as well as high-grade tumors (N=85). KC of inter-rater agreement was 0.46, statistically significant (p=0.03), indicating poor agreement between both T staging systems. Regarding OS, AJCC 7th (T1 and T2) and 8th (T1, T2, T3 and T4) T size stratification was not statistically different (P=0.42 and P=0.27, respectively). High-grade (71.4% vs 93.6%, P=0.005) and regional LNM (31.3% vs 81.4%, P=0.008) had worse 5-year OS in Cox multivariate analysis. Pts with tumor size>4cm or local invasion, high grade and LNM had 2.30, 7.11 and 4.37-fold increased risk of death respectively.
Conclusions
In our series, neither 7th nor 8th AJCC T size classifications adequately stratified prognostic groups or correlated survival for HN-STS pts. The 8th AJCC T4, the high-grade tumors and regional LNM demonstrated significant worse prognostic impact in pts harboring HN-STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15